Full-Time
Welcome Coordinator
Posted on 9/8/2026
CVS Health
10,001+ employees
Healthcare, insurance, PBM, and retail pharmacy
Compensation Overview
$17 - $25.65/hr
Company Historically Provides H1B Sponsorship
Fort Wayne, IN, USA
In Person
May require infrequent travel to other centers in the region.
Bachelor's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to CVS Health
See people who can refer or advise you
- Strong computer skills and basic knowledge of Google Suite.
- Professional phone etiquette.
- Fluency in Spanish, Polish, Russian, or another language spoken in the communities served where necessary.
- US work authorization.
- A flexible and positive attitude toward serving the patient population of older adults.
- A welcoming and nurturing attitude toward the patient population of older adults.
- A high level of integrity.
- Welcome patients and guests.
- Conduct visit check-in and assist patients with required forms.
- Collect co-pays.
- Update patient information and make changes in the electronic medical record platform.
- Schedule and reschedule appointments within the electronic medical records platform.
- Manage phone lines by answering calls, taking messages, and conducting outbound calls as instructed.
- Manage faxes in the electronic fax platform.
- Maintain the cleanliness of the Welcome and Community Room areas.
- Float to other centers in the region on an infrequent basis when required.
- Perform other duties as assigned.
- Experience in a customer service setting.
- Some college.
CVS Health operates as a diversified health services company in the United States, organized into Health Care Benefits, Pharmacy & Consumer Wellness, and Health Services. Its offerings include medical insurance products, retail and mail-order prescription drugs, and pharmacy benefit management (PBM) services, all connected through its integrated platform. By combining insurance, retail pharmacy, PBM, and health solutions, CVS Health coordinates care and controls costs across touchpoints for individuals, employers, and government programs. The company aims to lower health care costs while improving access and health outcomes for customers.
Company Size
10,001+
Company Stage
IPO
Headquarters
Woonsocket, Rhode Island
Founded
1963
Get referred to CVS Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $106.1 billion, up 7.3%, with adjusted EPS $2.58.
- CVS raised 2026 adjusted EPS guidance to $7.90-$8.10 and cash flow to $11.5 billion.
- Walgreens' 1,200-store closures through 2027 funnel prescriptions toward CVS locations.
What critics are saying
- FTC settlement on Caremark insulin practices forces transparency changes through 2036.
- CVS expects 340B pressure and Caremark membership declines in 2027.
- $175 billion liabilities and $3.12 billion annual interest burden constrain strategic flexibility.
What makes CVS Health unique
- Caremark, Aetna, and 9,000 stores create unmatched U.S. pharmacy-insurance integration.
- CVS handled 87 million PBM members and 37 million insured people in June 2026.
- CVS app now prices Eli Lilly Zepbound and Mounjaro for same-day pickup.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Company Equity
Wellness Program
Professional Development Budget
Paid Vacation
Paid Holidays
Company News
Walgreens is closing roughly 1,200 of its approximately 8,500 US locations through 2027, with many customers being redirected to nearby CVS pharmacies. The pattern is reshaping suburban pharmacy markets without direct competition. In August 2025, Walgreens completed a $10 billion sale to private equity firm Sycamore Partners, taking the 124-year-old chain private for the first time. Mike Motz was named chief executive, replacing Tim Wentworth. CVS is gaining market share without active expansion efforts. Federal and state rules require orderly prescription transfers when pharmacies close, often directing patients to the nearest CVS location. CVS and Walgreens together now handle nearly 40% of all US retail prescription sales. CVS benefits from owning Caremark, a dominant pharmacy benefit manager, providing vertical integration advantages.
CVS Health stock has declined 12.3% over the past month, sitting about 15% below its 52-week high, though it remains up 34% over the trailing twelve months. The company's revenue reached approximately $415 billion, up 7.4% year-over-year. Management raised its full-year 2026 adjusted earnings per share guidance by $0.60 to a range of $7.90 to $8.10. For 2027, the company anticipates membership declines at Caremark and continued 340B programme pressure, offset by Aetna's recovery, which added over $2 billion in adjusted operating income in the first half of 2026. Management considers a 2027 adjusted EPS outlook of at least $8.44 reasonable. Historically, CVS has experienced varied recovery periods following market downturns, with some rebounds taking years rather than months.
CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.
CVS Health has appointed Teresa Heitsenrether, a senior executive from JPMorgan Chase with extensive data and analytics experience, to its board of directors. The move follows the resignation of board member Larry M. Robbins. The appointment signals CVS Health's focus on technology and data-driven healthcare at the governance level. The company, valued at approximately $120bn, operates an integrated healthcare model spanning insurance, pharmacy benefits, and retail services. Heitsenrether's data expertise aligns with CVS Health's strategy to leverage digital capabilities and operational efficiency across its businesses, including Aetna and Caremark. The company faces challenges including high debt levels and reimbursement pressures in a competitive market alongside UnitedHealth Group and Cigna.
CVS Health reported second quarter revenue of $106.1 billion, beating analyst estimates of $99.41 billion by 6.7%. Adjusted earnings per share came in at $2.58, surpassing expectations of $1.85 by 39.4%. Management attributed strong performance to specialty pharmacy and Medicare Advantage, with CEO David Joyner noting improvements from actions taken in Aetna and Caremark. The company raised its full-year adjusted EPS guidance to $8 at the midpoint. However, analysts raised concerns about sustainability. Management acknowledged ongoing challenges in the 340B program and normalisation of script share gains from Rite Aid. To offset these headwinds, executives pointed to biosimilars and investments in service technology. The company has committed $20 billion over a decade to AI and technology investments, with operational savings already being realised.